MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure

By Thomas Thum, P. Galuppo, C. Wolf, J. Fiedler, S. Kneitz, L. V. Van Laake, P. Doevendans, C. Mummery, J. Borlak, A. Haverich and 4 more. Circulation, 2007

986 citations recorded by the source corpus.

Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3269f2952eee2612d88df32fb71021ea10c5cf39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

MicroRNAs in development and disease. (2011, background): “Early evidence that miRNAs were involved in cardiac pathology was attributed to the fact that they are differentially regulated during cardiac hypertrophy and failure in both rodent and human heart (102, 262, 407, 438, 533, 585, 600, 611, 626) (FIGURE 3).”
microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7 (2010, neutral): “These observations dystrophy (Eisenberg et al., 2007; Tatsuguchi et al., 2007; Thum et al., 2007).”
Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease (2010, neutral): “0001 Current smoker 6 (30) 5 (25) 4 (10) 0.”
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. (2009, background): “In addition, miRNA expression profiling studies demonstrate that the expression of specific miRNAs changes in diseased human hearts, pointing to the involvement of miRNAs in cardiomyopathies (15, 16).”
miR-21: a small multi-faceted RNA (2008, background): “One group also demonstrated a five-fold up-regulation in hypertrophic left cardioventricular tissue from human patients with end-stage systolic heart failure [22].”
Altered microRNA expression in human heart disease. (2007, background): “An oligonucleotide microarray study of a small number of samples (DCM, n = 6; control, n = 4) was recently published, and overall there was low concordance between data sets (16).”
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. (2016, background): “is activated in both mouse models and humans with pathological cardiac remodeling (262, 266).”